Tissue Regenix adds US patent related to ‘tissue matrices for bladder implantation’ to global exclusive licence portfolio
Tissue Regenix Group plc (AIM:TRX) (“Tissue Regenix” or “the Group”), the regenerative medical devices company, has received the formal notice of allowance for a patent covering the use of its dCELL® technology in creating tissue implants for bladder repair.
The Group has exclusive access to a range of patents protecting its core process in major markets, and is adding to these by working with its technology partner, the University of Leeds, to protect individual products and processes.
Tissue Regenix’s dCELL® decellularisation process removes DNA and other cellular material from animal and human tissue leaving an acellular tissue scaffold, which is not rejected by the patient’s body, and which can then be used to repair diseased or worn-out body parts. This is the latest patent covering the use of the dCELL® decellularisation process and follows the recent announcement that a patent had been granted in China for meniscal implants to repair knee injuries.
This latest patent adds to our fast-growing global portfolio, and will allow Tissue Regenix to use our dCELL® technology to help treat an array of urinary diseases and conditions in North America.
Driven by an ageing population and increase in obesity, the urology device market is one of the largest markets of the medical devices industry, expected to be worth more than $2.5bn in the US by 2016. Tissue Regenix has always planned for a global roll-out of dCELL® technology and shows our ambitious plans to address a wide-range of clinical needs.
Tissue Regenix has offices in the UK and US and is concentrated on the global commercialisation of its dCELL® technology.